We’re lowering our fair value estimate for Procter & Gamble due to the negative impact of currencies, but the firm’s underlying business is gaining traction and shares look modestly undervalued .
Our most popular articles and videos for the week ended January 23.
Despite an improving pipeline and slowing patent losses, a lackluster growth outlook will likely drive Pfizer to acquire assets in the near term.
DaVita Ranks First in Clinical Outcomes According to Government Reports
Jan. 26-30: Check your savings progress, assess your asset allocation, evaluate performance, size up your individual holdings, and get new ideas with model portfolios from Morningstar.
KCP&L Becomes Electric Vehicle Infrastructure Leader with Groundbreaking Announcement
Hedge Funds Learn Secrets Not So Safe
Syriza Victory in Greek Election Roils European Debate Over Austerity
Blackstone to Sell Sydney Property for $327 Million